Nghiên cứu xơ gan từ Fibroscan

Currently, liver biopsy is considered the gold standard method for the assessment of fibrosis in chronic liver disease, but the other non-invasive methods are being developed, in which liver stiffness (LS) rating by means of FibroScan device. The ratio measured by FibroScan values cirrhosis. Failure to obtain VM liver stiffness was observed in 6.9 percent of 46 patients the authors investigated. Female gender, older age and a higher Body Mass Index were statistically significantly related to failure to obtain cirrhosis. Comparative study of FibroScan results for liver biopsy in patients with cirrhosis showed that for a cutoff value of 6.8 kpa, the LS measure liver stiffness with positive value (PPV) of 97,2 percent, a negative value (NPV) of 34.2 percent, 59.2 percent sensitivity, 92.6 percent specificity for the presence of significant fibrosis (at least F2 Metavir), with a volume diagnosis of 76.1 percent (AUC 0761). Evaluation of patients with cirrhosis of Fibroscan test demonstrated that liver stiffness LS is a good predictor for the presence of cirrhosis, with a sensitivity of about 88 percent for a cut-off value of 14 kPa . In summary, fibroscan is a promising method for the evaluation of patients with cirrhosis, allowing precise cirrhosis and slight differences and no fibrosis (F0-F1) from fibrosis significant (F2-F4).